Article
The Rapid Reduction of Infection-Related Visits and Antibiotic Use Among People With Cystic Fibrosis After Starting Elexacaftor-Tezacaftor-Ivacaftor.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 30 Sept 2022
Miller Aaron C, Harris Logan M, Cavanaugh Joseph E, Abou Alaiwa Mahmoud, Stoltz David A, Hornick Douglas B, Polgreen Philip M
Abstract excerpt
BACKGROUND: People with cystic fibrosis (CF) routinely suffer from recurrent sinopulmonary infections. Such infections require frequent courses of antimicrobials and often involve multidrug-resistant organisms. The goal of this study was to identify real-world evidence for the effectiveness of elexacaftor-tezacaftor-ivacaftor (ELX/TEZ/IVA) in decreasing infection-related visits and antimicrobial use in people...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.